Topic Advisory Panel Members’ Collection Series: Immunization and Vaccines for Infectious Diseases

A topical collection in Vaccines (ISSN 2076-393X). This collection belongs to the section "Vaccines against Tropical and other Infectious Diseases".

Viewed by 6941

Editors


E-Mail Website
Collection Editor
Department of Biomedical Sciences, University of Pikeville, Coal Building, Office 718, 147 Sycamore Street, Pikeville, KY 41501, USA
Interests: infectious diseases; tuberculosis; vaccines
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Collection Editor
Department of Biological Sciences, Rensselaer Polytechnic Institute, Troy, NY 12180, USA
Interests: yeast-based vaccines; yeast-based screening of chemicals
Special Issues, Collections and Topics in MDPI journals

Topical Collection Information

Dear Colleagues,

Our Topical Collection will be a “Topic Advisory Panel Collection” that will cover all the topics relevant to immunization for infectious diseases. Human history has faced several pandemic threats, including influenza, SARS2, and COVID-19. The big challenge in responding to pandemic diseases is that vaccines may not exist, or existing vaccines may not be effective against them. Therefore, this collection will be an ideal forum where scientists can share their latest research findings on immunization and vaccines related to infectious diseases, particularly Inflenzam, SARS-CoV-2, HIV, and tuberculosis. In this collection, original research articles, case studies, editorials, and reviews are welcome.

We look forward to receiving your manuscript.

Dr. Shumaila Hanif
Dr. Ravinder Kumar
Collection Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccine
  • immunization
  • infectious diseases
  • influenza
  • SARS2
  • COVID-19
  • SARS-CoV-2
  • HIV
  • tuberculosis

Published Papers (2 papers)

2023

14 pages, 1512 KiB  
Article
Assessment of Enterovirus Excretion and Identification of VDPVs in Patients with Primary Immunodeficiency in India: Outcome of ICMR–WHO Collaborative Study Phase-I
by Madhu Chhanda Mohanty, Mukesh Desai, Ahmad Mohammad, Amita Aggarwal, Geeta Govindaraj, Sagar Bhattad, Harsha Prasada Lashkari, Liza Rajasekhar, Harish Verma, Arun Kumar, Unnati Sawant, Swapnil Yashwant Varose, Prasad Taur, Reetika Malik Yadav, Manogat Tatkare, Mevis Fernandes, Umair Bargir, Sanjukta Majumdar, Athulya Edavazhippurath, Jyoti Rangarajan, Ramesh Manthri and Manisha Ranjan Madkaikaradd Show full author list remove Hide full author list
Vaccines 2023, 11(7), 1211; https://doi.org/10.3390/vaccines11071211 - 6 Jul 2023
Cited by 1 | Viewed by 2028
Abstract
The emergence of vaccine-derived polioviruses (VDPVs) in patients with Primary Immunodeficiency (PID) is a threat to the polio-eradication program. In a first of its kind pilot study for successful screening and identification of VDPV excretion among patients with PID in India, enteroviruses were [...] Read more.
The emergence of vaccine-derived polioviruses (VDPVs) in patients with Primary Immunodeficiency (PID) is a threat to the polio-eradication program. In a first of its kind pilot study for successful screening and identification of VDPV excretion among patients with PID in India, enteroviruses were assessed in stool specimens of 154 PID patients across India in a period of two years. A total of 21.42% of patients were tested positive for enteroviruses, 2.59% tested positive for polioviruses (PV), whereas 18.83% of patients were positive for non-polio enteroviruses (NPEV). A male child of 3 years and 6 months of age diagnosed with Hyper IgM syndrome was detected positive for type1 VDPV (iVDPV1) with 1.6% nucleotide divergence from the parent Sabin strain. E21 (19.4%), E14 (9%), E11 (9%), E16 (7.5%), and CVA2 (7.5%) were the five most frequently observed NPEV types in PID patients. Patients with combined immunodeficiency were at a higher risk for enterovirus infection as compared to antibody deficiency. The high susceptibility of PID patients to enterovirus infection emphasizes the need for enhanced surveillance of these patients until the use of OPV is stopped. The expansion of PID surveillance and integration with a national program will facilitate early detection and follow-up of iVDPV excretion to mitigate the risk for iVDPV spread. Full article
Show Figures

Figure 1

13 pages, 881 KiB  
Article
Evaluation of the Effectiveness of the Policy of Holding the Second Dose of Vaccination: Lessons from the Outbreak in Ho Chi Minh City
by Vu Thi Thu Trang, Le Van Truong, Truong Van Dat, Randa Elsheikh, Nguyen Tuan Anh, Dang Xuan Thang, Vo Viet Thang, Abdelrahman M. Makram, Nguyen Tien Huy and Nagasaki University Collaborative
Vaccines 2023, 11(2), 293; https://doi.org/10.3390/vaccines11020293 - 29 Jan 2023
Viewed by 3363
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has caused a lot of ethical controversy in the equal provision of healthcare, including vaccination. Therefore, our study was designed to assess the impact of Ho Chi Minh City’s policy to hold the second dose of the [...] Read more.
The coronavirus disease 2019 (COVID-19) pandemic has caused a lot of ethical controversy in the equal provision of healthcare, including vaccination. Therefore, our study was designed to assess the impact of Ho Chi Minh City’s policy to hold the second dose of the COVID-19 vaccine. Using a cross-sectional study design to assess low saturation of peripheral oxygen (SPO2) risk based on vaccination status, we included patients who were confirmed to have SARS-CoV-2 and were treated at home. The stepwise method was used to determine participants’ low SPO2 risk-related factors. The average age of the 2836 respondents was 46.43 ± 17.33 (years). Research results have shown that seven factors are related to the low SPO2 status of participants, including age, sneezing, shortness of breath, coughing, and fainting as COVID-19 symptoms, the number of people living with COVID-19, and a history of lung disease. A statistically significant (p = 0.032) finding in this study was that fully vaccinated patients had a 6% lower risk of low SPO2 compared to the first dose less than 21 days group. This result was similar in the vaccine holder group (p < 0.001). Holding the second dose of the COVID-19 vaccine is associated with a lower SPO2 risk than that of fully vaccinated patients. Therefore, this approach should be considered by governments as it could bring a greater benefit to the community. Full article
Show Figures

Figure 1

Back to TopTop